Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05038384 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Palliative, Rehabilitation, and Integrated Medicine Handbook for Self Care at Work

Start date: December 3, 2020
Phase:
Study type: Observational

This study investigates the usefulness of the Self Care at Work Handbook in order to generate an improved version. Information from this study may help researchers identify potential factors associated with perception and usefulness of the Self Care at Work Handbook.

NCT ID: NCT05017597 Withdrawn - Neoplasms Clinical Trials

Online Cancer-Related Fatigue Management

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Many individuals who have had cancer experience functional limitations during and after their treatments. The most common side effect from cancer treatment that restricts cancer survivors' completion of daily activities is cancer-related fatigue. Here, we propose to investigate whether an interprofessional approach that targets physiologic, psychologic, and ecological factors will minimize cancer-related fatigue and enhance daily life participation for volunteer cancer survivors living in the community. The interprofessional team will include occupational therapy professor and students from Eastern Kentucky University (EKU), physical therapy and dietitian professors and their students from the University of Dayton, and instructional design instructor from EKU. The approach will include (1) individualized exercise programs-via physical therapy; (2) problem-solving strategies including modifying the environment or activity -via occupational therapy; (3) goal development via physical and occupational therapy; and (4) cancer-related fatigue education via instructional design. We hypothesize that this approach will result in participants experiencing less fatigue, increasing their mobility, improving their quality of life, and being more satisfied with how they perform daily activities.

NCT ID: NCT05010096 Withdrawn - Clinical trials for Metastatic Malignant Solid Neoplasm

BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors

Start date: March 22, 2022
Phase: Phase 1
Study type: Interventional

This phase Ib trial finds out the best dose, possible benefits and/or side effects of BAY1895344 and copanlisib in treating molecularly selected patients with solid tumors that have spread to other places in the body (advanced). BAY1895344 and copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving BAY1895344 and copanlisib together may help control the progression of the disease in patients with advanced solid tumors.

NCT ID: NCT04987281 Withdrawn - Clinical trials for Lung Non-Small Cell Carcinoma

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

Start date: January 26, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial studies the use of Ion robotic bronchoscope with a mobile computed tomography (CT) scanner to biopsy tumors and inject a fluorescent dye called indocyanine green to mark the tumor during surgery in patients with stage I non-small cell lung cancer or cancer that has spread to the lung (lung metastases). Sometimes small tumors or those that are not on the surface of the lung can be challenging to remove without making larger incisions. Injecting the dye, may help doctors see the tumor more easily, which may allow for smaller incisions and by being able to see the tumor, doctors may be better able to decide where to make the incisions in order to get all of the tumor out.

NCT ID: NCT04878484 Withdrawn - Clinical trials for Advanced Solid Tumor

Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors

Start date: August 11, 2021
Phase: Phase 1
Study type: Interventional

TCRT-ESO-A2 is an autologous cell therapy comprised of a subject's T cells stimulated ex vivo and transduced with a lentiviral vector encoding an affinity enhanced TCR targeting tumor-associated antigen NY-ESO-1. This study will investigate the safety, tolerability, activity, and pharmacokinetics/ pharmacodynamics of TCRT-ESO-A2 infusion. A maximum tolerated dose study of TCRT-ESO-A2 in subjects with advanced malignancies expressing NY-ESO-1 is considered to be an acceptable risk. Once safety, tolerability, and pharmacokinetic/pharmacodynamic data are available, the activity of TCRT-ESO-A2 in NY-ESO-1-positive tumors may be explored further.

NCT ID: NCT04820894 Withdrawn - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Perception of Cure Among Patients With Metastatic Cancer

Start date: October 30, 2021
Phase:
Study type: Observational

This study collects information about perception of cure among patients with cancer that has spread to other places in the body (metastatic). This study aims to determine patients' perception (knowledge) before starting immunotherapy and if differences exist in understanding of treatment to stimulate or restore the ability of the body's immune (defense) system to fight infection and disease (immunotherapy) based on social and economic factors or on race/ethnicity.

NCT ID: NCT04811833 Withdrawn - Clinical trials for Gastrointestinal Stromal Tumors

Gastrointestinal Anastomosis Using MonoPlus® Suture

GASTROMO
Start date: July 2022
Phase:
Study type: Observational

The primary aim of this study is to collect clinical data on the performance of MonoPlus® suture applied in routine clinical practice. Diverse parameters are to be used to assess the safety and efficacy of MonoPlus® suture for gastrointestinal anastomosis construction. This study has been designed to implement an action within the framework of a proactive Post Market Clinical Follow up (PMCF) activity.

NCT ID: NCT04809012 Withdrawn - Solid Tumor Clinical Trials

Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors

Start date: June 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected solid tumors.

NCT ID: NCT04803630 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study

Start date: May 6, 2021
Phase: Early Phase 1
Study type: Interventional

This early phase I trial evaluates the effect of thermal therapy on depression with or without sleep disturbance in cancer survivors. Thermal therapy may help improve quality of life, physical capacity, fatigue, and enhance positive mood and sleep quality. The purpose of this study is to evaluate the potential of thermal therapy to improve patient's quality of life by reducing symptoms of depression, sleep disruption, fatigue and anxiety in cancer survivors.

NCT ID: NCT04799431 Withdrawn - Clinical trials for Colorectal Cancer Metastatic

Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal Cancer

Start date: May 3, 2023
Phase: Phase 1
Study type: Interventional

Phase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).